NCIC CLINICAL TRIALS GROUP

GENITO URINARY

DISEASE SITE COMMITTEE MEETING AGENDA

Delta Chelsea Hotel, Toronto, Ontario Sunday, April 18, 2004 - 9:00 a.m. - 3:30 p.m. Room: Churchill Ballroom B

Chair: Martin Gleave

9:00 a.m. Welcome, Approval of Minutes and Chairman's report M Gleave

CURRENT NCIC CTG PHASE III TRIALS

9:05 a.m.	PR.3	P Warde
9:10a.m.	PR.7/PR.7 bone sub study	J Crook/L Klotz
9:20 a.m.	PR.8	B Donnelly
9:25 a.m.	PR.9	R Choo
9:30 a.m.	PR.10 / ACOSOG	J Crook/ N Fleshner
9:40 a.m.	BL.7 / EORTC 30987	M Moore/ E Winquist
9:45 a.m.	BL 8 / EORTC 30994	L Wood
9:55 a.m.	BL.10	L Klotz
10:00 a.m.	PRP.1	N Fleshner

TRIALS APPROVED/PENDING ACTIVATION

10:05 a.m. BL.11 Lacombe

10:15 a.m. Coffee Break

NCIC CTG IND TRIALS

10:30 a.m. IND.143: MG 98 Renal Cell Phase II	E Winquist
10:35 a.m. IND.153: OGX-011 Prostate Ca Phase I	K Chi
10:40 a.m. IND.154: OGX-011 + Taxotere Phase I	K Chi
10:45 a.m. IND.161: Triapine Phase	J Knox
10:50 a.m. IND.165 (OGX docetaxel prostate)	K Chi
10:55 a.m. IND.167 (BAY 43-9006 prostate)	K Chi

CURRENT COUG TRIALS

11:00 a.m. Iressa for Rising PSA post RP	L Klotz
11:10a.m. Taxotere as Second Line in HRPC	F Saad
11:20 a.m. Antigenics Oncophage in RCC post nephrectomy	S Tanguay
44.00 A / 1.0 /l D / CA 1 D ' / D I '	

11:30 a.m. Actonel for the Prevention of Androgen Deprivation Bone Loss in

Non-Metastatic Prostate Cancer F. Saad

CLOSED CUOG TRIALS

11:40 a.m. CUOG P-01b (NHT Taxotere)

M Gleave
11:50 a.m. Taxotere + high dose Calcitriol

K Chi

12 NOON LUNCH

TRIALS UNDER DEVELOPMENT

1:00 p.m.	Antisense bcl-2 + Taxotere in HRPC	K Chi
1:05 p.m.	Role of Delayed Treatment for Early Stage RCCa	M Jewett
1:10 p.m.	NHT+ Taxotere prior to XRT	M McKenzie
1:15 p.m.	NHT + Taxotere prior to RP	K Chi/ M Gleave
1:20 p.m.	START: Surveillance Vs intervention early CaP	R Choo
1:25 p.m.	Conventional vs hypofraction IMRT	C. Catton

REPORT FROM DOGS

1:30 p.m.	Advanced Prostate Cancer	K Chi
1:40 p.m.	Localized Prostate Cancer	L Klotz
1:50 p.m.	Superficial Bladder	L Lacombe
2:00 p.m.	Advanced Bladder	E Winquist
2:10 p.m.	Kidney	S Tanguay
2:20 p.m.	Testes	P Warde

2:30 p.m. Coffee Break

OTHER TRIALS UNDER CONSIDERATION

2:45 p.m. EORTC Intermediate Risk Testes Trial Update E Winquist / P Warde

CTSU TRIALS

2:50 p.m. CTSU Presentation

3:00 p.m. Endorsed by NCIC CTG

REC.1/CALGB 90206 A Phase III trial of interferon alpha (IFNA) or IFNA plus bevacizumab

in advanced renal carcinoma

Target accrual 700 Current accrual 31

3:05 p.m. Available for endorsement: Active protocols

RTOG P-0014: Phase III randomized study of patients with high-risk, hormone naïve prostate cancer: Androgen blockade with 4 cycles of immediate chemotherapy versus

androgen blockade with delayed chemotherapy

Target accrual 1050 Current accrual 10

3:10 p.m. **Protocols in development**

CALGB 90202/CTSU 90202

A randomized double blind, placebo controlled phase III study of early versus standard Zoledronic Acid to prevent skeletal related events in men with prostate cancer metastatic to bone

Randomized phase III study of estramustine and docetaxel versus estramustine, docetaxel and bevacizumab in patients with hormone refractory prostate cancer

3:20: p.m. **CUOG AGM**

Other Business

Fellowship Opportunities: NCIC CTG/ CUOG

3:30 p.m. Meeting Adjourned